DOI QR코드

DOI QR Code

Antimicrobial Activities of Novel 3-Substituted [1,2,4] Triazolo[4,3-b]pyridazines Derivatives

  • Received : 2014.02.26
  • Accepted : 2014.06.12
  • Published : 2014.08.20

Abstract

A noval derivatives of 3-substituted[1,2,4]triazolo[4,3-b]pyridazine (4a-4o) and 7,8,9,10-tetrahydrobenzo[4,5] thieno[2,3-d][1,2,4]triazolo[4,3-b]pyridazine (7a-7l) is prepared by the reaction of heteroaryl hydrazone from the aldehyde and pyridazinohydrazine derivative, followed by subjecting the intermediate directly to oxidative cyclization employing the mixture of $Me_4NBr$ and Oxone. These derivatives were subjected to preliminary antimicrobial activities against microorganism. All these compounds exhibit good to moderate activity.

Keywords

INTRODUCTION

Omnipresent interest on the synthesis of 1,2,4 triazole derivatives are owing to their diverse use in organocatalysis, materials science and biological applications. Most of the 1,2,4-triazole structural motif exhibit a wide spectrum of biological properties including antimicrobial, antitubercular, serotonergic, anti-allergy, CNS depressant, antiinflammatory, anticonvulsants and anti-cancer activities.1 The recent exploratory result reveals that 1,2,4 triazoles derivatives performed as inhibitor of HIV-integrase and methionine aminopeptidase.2 Besides, many powerful and popular drugs constituted with 1,2,4 triazoles system are commercially available in the market e.g., Fluconazole, Itraconazole, varozole, voriconazole, Loreclezole, Anastrolzole and triazolam (Figure 1).

Figure 1.Drugs containing 1,2,4 triazole moiety.

Attention to synthesis of several biologically active compounds with pyridazine ring is an emerging practice due to its numerous activity against microbial, fungal, viral, tumor, hypertensive, tubercular and cancer cells.3 In addition, a heterocyclic system extended with the pyridazines moiety are found to be an important pharmacore to construct a potentially new bio-active molecule in modern medicinal chemistry.4 In particularly, the physiological and pharmacological activity can be attractively enhanced by introducing a thieno group in to the pyridazine motif.5 Furthermore, triazolopyridazine derivatives have been reported to possess anti-HAV activity, c-Met kinase inhibitor, GABAA and adenine receptors.6

Most common and widely used method to construct 1,2,4-triazole system is the oxidative cyclization of hydrazone. Very recently, we have reported the one pot synthesis of triazolopyridazine derivative and thieno-triazolopyridazine derivatives using Me4NBr and oxone.7 As a continuation, our interest to investigate the antimicrobial activities of the noval triazolopyridazine derivatives, we report herein the antibacterial and antifungal activity of the compound 3-substituted[1,2,4]triazolo[4,3-b]pyridazine (4a–4o) and 7,8,9,10-tetrahydrobenzo[4,5]thieno[2,3-d][1,2,4]triazolo [4,3-b]pyridazine (7a–7l) against the bacterial strain (Staphylococcus aureus and Bacillus subtilis-Gram positive, Escherichia coli and Pseudomonas aeruginosa-Gram negative) and fungi (Aspergillus niger and Aspergillus flavus) using the broth dilution method.

 

EXPERIMENTAL

All reagents were purchased from commercial suppliers and were used without purification. Melting points were determined in Buchi B-545melting point apparatus and were uncorrected. 1H NMR and 13C NMR spectra were recorded on a Bruker Advance-400 & 300 NMR MHZ spectrometer in DMSO-d6 & CDCl3 solution using TMS as an internal reference and 13C NMR were recorded at 100 & 75 MHz. Mass spectra were recorded on LC-MS-Agilent 1200 series, Carbon, Hydrogen, Nitrogen and Sulphur were analyzed on Elementor instrument. All these compounds were purified by flash column Chromatography using 230–400 mesh silica gel.

General Procedure for the Synthesis of 3-Substituted Triazolopyridazine

A mixture of corresponding hydrazinylpyridazine 1 or 5 (1 mmol) and aldehyde 2 (1.1 mmol) in ethanol (5 mL) was heated at 60 ℃ for 0.5 h. The formation of hydrazone was checked by TLC and the reaction mixture was cooled to rt. Oxone (1.5 mmol) was added to the mixture at rt followed by tetramethyl ammonium bromide (0.2 mmol) and the resulting mixture was heated at 60 ℃ for another 5 h. The mixture was cooled to rt and extracted with dichloromethane (2 × 25 mL), dried over anhydrous sodium sulfate and concentrated to obtain a residue which was purified by column chromatography using hexane/ethyl acetate as eluent to furnish the desired triazolopyridazines 4 and 7 (See reference no; 7 for supporting information).

 

RESULTS AND DISCUSSION

Target compounds 4a–4o and 7a–7l were prepared by one-pot synthesis. At first, hydrazinylpyridazine (1 or 5) was treated with various aldehydes to obtain the heteroarylhydrazones (3 or 6) which was subjected directly to oxidative cyclization with the mixture of Me4NBr (20 mol%) and oxone (1.5 equiv.) to acquire the triazolopyridazine derivatives of 4a–4o and 7a–7l (Scheme 1 & 2) in 80–95% yields.8

Scheme 1.a) Aldehyde, ethanol, 60 ℃, 30 min (b) teramethylammonium bromide/oxone, 60 ℃, 5 h.

Scheme 2.(a) Aldehyde, ethanol, 60 ℃, 30 min (b) teramethylammonium bromide/oxone, 60 ℃, 5 h.

Twenty seven compounds were synthesised and their structure was confirmed by NMR, mass spectroscopy and elemental analysis. All the synthesized compounds 4a–4o and 7a–7l were screened for their in vitro antibacterial activity against Gram-positive (Staphylococcus aureus and Bacillus subtiis) and Gram-negative (Escherichia coli and Pseudomonas aeruginosa) bacteria strains using broth dilution method for determination of MIC.9 This activity was compared to a well-known commercial antibiotic, such as ampicillin. Screening results revealed that the compounds 4a–4o and 7a–7l displayed good to moderate activities towards the tested antibacterial strains. On the basis of the zone of inhibition produced against test bacteria, compounds 4d, 4l, 4m, 7f and 7i found to have significant activity against both Gram-positive and Gram-negative bacterial strains, whereas the compounds 4c, 4g and 7c showed good activity against Gram-positive bacteria, and also 4i and 7g exhibited potent activities against the Gram-negative bacterial strains. These results are summarised in (Table 1, Figure 2).

Table 1.In vitro antibacterial screening results of the tested compounds 4a−4o and 7a−7l

Figure 2.Diameter of growth of inhibition of selected compounds of antibacterial activity.

Rest of all compounds displayed week activity against the tested bacterial strains. In these case, the increased activity could be attributed the presence of fluro, chloro, acid, ester, nitro, pyridyl, thiophene, allyl and phenoxy group in these compounds. All the twenty seven compounds were also subjected to their antifungal activities against the fungi namely, Aspergillus flavus and Aspergillus Niger. Fluconazole was used as standard for the comparison of antifungal activity of the compounds 4a–4o and 7a–a7l.

This result indicated that almost all the compounds have week to good antifungal activity against the test fungi. The compound 4d, 4g, 4h, 7c, and 7f were found to have maximum inhibition zone (77%) whereas the compound 4l, 4n and 7i exhibited more than 65% inhibition zone against fungi, Aspergillus flavus and Aspergillus niger (Table 2, Figure 3).

Table 2.In vitro antifungal screening results of the tested compounds 4a 4o and 7a–7l.

Figure 3.Diameter of growth of inhibition of selected compounds of antifungal activity.

In conclusion, we have synthesized a novel series 3-methylhydrazinopyridazine (4a–4o) and 4-hydrazinyl-6,7,8,9-tetrahydro[1]benzothieno[2,3-d]pyridazine derivative (7a–7l) using the mixture of Me4NBr and Oxone. All newly synthesized compounds were tested for their antimicrobial activities and showed fairly to good activities against the bacteria and fungi. However, in whole series, compound 4d and 4f possess potent antimicrobial activity.

References

  1. (a) Ulusoy, N.; Gursoy, A.; Otuk, G. II Farmaco 2001, 56, 947-952. https://doi.org/10.1016/S0014-827X(01)01128-4
  2. (b) Papakostantinou, S.; Garoufalias, N.; Pouli, P.; Marakos, A.; Ladas, A.C. II Farmaco 2002, 57, 973-977. https://doi.org/10.1016/S0014-827X(02)01227-2
  3. (c) Kucukguzel, I. I.; Kucukguzel, S. G.; Rollas, S.; Kiraz, M. Bioorg. Med. Chem. Lett. 2001, 11, 1703-1707. https://doi.org/10.1016/S0960-894X(01)00283-9
  4. (d) Patel, N. B.; Khan, I. H.; Rajani, S. D. Eur. J. Med. Chem. 2010, 45, 4293-4299. https://doi.org/10.1016/j.ejmech.2010.06.031
  5. (e) Shiradkar, M.; Kumar, G. V. S.; Dasari, V.; Tatikonda, S.; Akula, K. C.; Shah, R. Eur. J. Med. Chem. 2007, 42, 807-816. https://doi.org/10.1016/j.ejmech.2006.12.001
  6. (f) Parmar, S. S.; Gupta, G. A. K.; Singh, H. H.; Gupta, T. K. J. Med. Chem. 1972, 15, 999-1000. https://doi.org/10.1021/jm00279a033
  7. (g) Wang, L. C.; Tu, C. H.; Wang, J. H.; Lee, G. H. Molecules 2006, 11, 169-176. https://doi.org/10.3390/11020169
  8. (h) Zitouni, G. T.; Kaplanciki, Z. A.; Ozdemir, A.; Chevallet, P.; Kandilci, H. B.; Gumusel, B. Arch. Pharm. Chem. Life. Sci. 2007, 11, 586-590.
  9. (i) Sarva, M. C.; Romeo, G.; Guerrera, F.; Siracusa, M.; Alerno, L.; Russo, F.; Cagnotto, A.; Goegan, M.; Mennin, T. Cheminform. 2010, 33, 2002-2004.
  10. (j) Holla, B. S.; Veerendra, B.; Poojary, M. K. Eur. J. Med. Chem. 2003, 38, 759-767. https://doi.org/10.1016/S0223-5234(03)00128-4
  11. (k) Parmar, S. S.; Chaudhary, M.; Chaudhary, S. K.; Kumar, S.; Spiro, H. R. J. Pharm. Sci. 1977, 66, 971-975. https://doi.org/10.1002/jps.2600660717
  12. (a) Shimizu, S.; Endo, T.; Izumi, K.; Mikamiyama, H. Org. Process Res. Dev. 2007, 11, 1055-1058. https://doi.org/10.1021/op700116y
  13. (b) Marino, J. P., Jr.; et al. J. Med. Chem. 2007, 50, 3777-3785. https://doi.org/10.1021/jm061182w
  14. (a) Unqureanu, M.; Mangalagiu, I.; Grosu, G.; Petrovanu, M. Ann. Pharm. Fr. 1997, 55, 69-72.
  15. (b) Galtie, C.; Mavel, S.; Snoeck, R.; Andre, G.; Pannecouque, C.; Witvrouw, M.; Balzarini, J.; Clercq, E. D.; Gueiffier, A. Antivir. Chem. & Chemother. 2003, 14, 177-182. https://doi.org/10.1177/095632020301400402
  16. (c) Islam, M.; Siddiqui, A. A.; Rajesh, R. Acta Pol Pharm. 2008, 65, 441-447.
  17. (d) Yassin, F. A. Chem. Heterocycl. Comp. 2009, 45, 997-1003. https://doi.org/10.1007/s10593-009-0381-9
  18. (e) Zhou, J.; Fan, H. T.; Song, B. A.; Jin, L. H.; Bhadury, P. S.; Hu, D. Y.; Yang, S. Phosphorus, Sulfur, Silicon Relat. Elem. 2010, 186, 81-87. https://doi.org/10.1080/10426507.2010.482543
  19. (f) Bloomer, L. C.; Wotring, L. L.; Townsend, L. B. Cancer Res. 1982, 42, 100-106.
  20. (g) Katz, D. J.; Wise, D. S.; Townsend, L. B. J. Med. Chem. 1982, 25, 813-321. https://doi.org/10.1021/jm00349a009
  21. (h) Corina, M.; Casiraghi, G.; Zetta, L. C. J. Org. Chem. 1991, 56, 5466-5468. https://doi.org/10.1021/jo00018a053
  22. (i) Abubshait, S. A. Molecules 2007, 12, 25-42. https://doi.org/10.3390/12010025
  23. (j) Yokoyama, M.; Tanabe, T.; Toyoshima, A.; Togo, H. Chem Lett. 1994, 517, 265-268.
  24. (k) Mantu, D.; Luca, M. C.; Moldoveanu, C.; Zbancioc, G.; Mangalagiu, I. Eur. J. Med. Chem. 2010, 45, 5164-5168. https://doi.org/10.1016/j.ejmech.2010.08.029
  25. (l) Malinka, W.; Redizicka, A.; Lozach, O. II Farmaco 2004, 59, 457-462. https://doi.org/10.1016/j.farmac.2004.03.002
  26. (a) Albright, J. D.; Moran, D. P.; Wright, W. B.; Collins, J. P.; Beer, B.; Lipa, A. S.; Greenblatt, E. N. J. Med. Chem. 1981, 24, 592-600. https://doi.org/10.1021/jm00137a020
  27. (b) Biagi, G.; Giorgi, I.; Livi, O.; Manera, C.; Scartoni, V.; Lucacchini, A.; Senatore, G. II Farmaco 1996, 51, 601-608.
  28. (c) Atack, J. R.; et al. J. Pharmacol. Exp. Ther. 2010, 332, 17-25. https://doi.org/10.1124/jpet.109.157909
  29. (d) Licata, S. C.; Platt, D. M.; Ruedi-Bettschen, D. R.; Atack, J. R.; Dawson, G. R.; Van Linn, M. L.; Cook, J. M.; Rowlett, J. K. Neuropharmacology. 2010, 58, 357-364. https://doi.org/10.1016/j.neuropharm.2009.10.004
  30. (a) El-Dean, A. M. K.; Gaber, A. E. M.; El-Gaby, M. S. A.; Eyada, H. A. Cheminform. 2004, 35, 321-344.
  31. (b) Singh, A. K.; Hedge, G. L.; Khanum, S. A.; Shashikanth, S. Indian J. Pharm. Sci. 2005, 67, 210-215.
  32. (c) Pieretti, S.; Ominici, L. D.; Di Giannuario, A.; Cesari, N.; Dal Piaz, V. Life Sci. 2006, 79, 791-800. https://doi.org/10.1016/j.lfs.2006.02.026
  33. (d) Zaher, A. F. A.; Refaat, H. M.; Fawzy, O. M. Bull. Fac. Pharm. Cairo. Univ. 2009, 47, 69-75.
  34. (a) Street, L. J.; et al. J. Med. Chem. 2004, 47, 3642-3657. https://doi.org/10.1021/jm0407613
  35. (b) Shamroukh, A. H.; Ali, M. A. Arch. Pharm. 2008, 341, 223-230. https://doi.org/10.1002/ardp.200700181
  36. (c) Albrecht, B. K.; et al. J. Med. Chem. 2008, 51, 2879-2882. https://doi.org/10.1021/jm800043g
  37. Sembian Ruso, J.; Rajendiran, N.; Senthilkumaran, R. J. Korean Chem. Soc. 2013, 57(5), 606. http://dx.doi.org/10.5012/jkcs.2013.57.5.606.
  38. National committee for Clinical Laboratory Standards, Methods for Dilution Antimicrobial Susceptibility Test for Bcateria that Grow Aerobically, Approved Standard-Fith Edition. M7-A5 Ed. NCCLS, Wayne, PA, 2000, 1-33.

Cited by

  1. Synthesis and bioevaluation of 6-chloropyridazin-3-yl hydrazones and 6-chloro-3-substituted-[1,2,4]triazolo[4,3-b]pyridazines as cytotoxic agents vol.86, pp.None, 2014, https://doi.org/10.1016/j.bioorg.2019.01.049